Development of Thiazole-based VEGFR-2 Targeted Agents: A Comprehensive Review of Cytotoxic and Anticancer Activities
Archives of Pharmacy and Pharmaceutical Sciences · 05.06.2026 · 5-20
DOI: 10.29328/journal.apps.1001071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Pharmacy and Pharmaceutical Sciences, online erschienen am 05.06.2026. Verfasst von Mehtab Alam und 5 weiteren Autor:innen. Die Arbeit nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
One of the best-proven molecular targets in the treatment of cancer is vascular endothelial growth factor receptor-2 (VEGFR-2). Because it plays an important role in tumor angiogenesis, proliferation, and metastasis. FDA-approved VEGFR-2 inhibitors have proven to have clinical efficacy in managing various malignancies. Anti-cancer activity of approved agents such as sorafenib (IC50 = 1 µM - 10 µM), sunitinib (IC50 = 1 µM - 5 µM), and pazopanib (IC50 = 1 µM - 3 µM) has been demonstrated. However, their therapeutic use can result in off-target toxicities. Moreover, acquired resistance mechanisms have been observed as well. They also have poorly selective means of action. The 1,3,4-thiadiazole scaffold has become an important heterocyclic compound of medicinal chemistry due to its mesoionic character, versatility in structures, and pharmacological attributes. This review presents a systematic study of the earlier developments in the rational design, synthesis, SAR, and cytotoxicity evaluation of thiazole-based VEGFR-2 inhibitors. In this review, the molecular mechanisms of VEGFR-2 inhibitors and their biological activities against a variety of cancer cell lines in terms of their ability to induce apoptosis, modulate cell cycle, anti-metastatic properties, and in silico approaches. The recently added thiazole derivatives display very good VEGFR-2 inhibitory activities with IC50 values ranging from 0.055 to 0.194 µM, potent antiproliferation activities with IC50 values of 1.5-15 µM, good selectivity indices (3-20-fold), and anticancer activities through different mechanisms of action that are more favorable than the established drugs.
Zitieren
APA
Alam, M., Khan, A. A., Shabnam, M. S., Hasan, S. M., Anas, M., & Zaidi, S. M. H. (2026). Development of Thiazole-based VEGFR-2 Targeted Agents: A Comprehensive Review of Cytotoxic and Anticancer Activities. Archives of Pharmacy and Pharmaceutical Sciences, 5-20. https://doi.org/10.29328/journal.apps.1001071
Vancouver
Alam M, Khan AA, Shabnam MS, Hasan SM, Anas M, Zaidi SMH. Development of Thiazole-based VEGFR-2 Targeted Agents: A Comprehensive Review of Cytotoxic and Anticancer Activities. Archives of Pharmacy and Pharmaceutical Sciences. 2026:5-20. doi:10.29328/journal.apps.1001071
BibTeX
@article{Alam2026,
author = {Alam, Mehtab and Khan, Ahsan Ahmad and Shabnam, Mir Snober and Hasan, Syed Misbahul and Anas, Mohd and Zaidi, Syed Mehndi Hasan},
title = {Development of Thiazole-based VEGFR-2 Targeted Agents: A Comprehensive Review of Cytotoxic and Anticancer Activities},
journal = {Archives of Pharmacy and Pharmaceutical Sciences},
year = {2026},
pages = {5--20},
doi = {10.29328/journal.apps.1001071}
}
EUVIMED